I think you have a very valid point. We may have to work Leronlimab’s magic out in third world in order to make the first world notice. Although 28 patients are a small number, those results might get regional attention in Asia. That would be huge! Then if we can get similar arrangements in Brazil, we might have more demand than supply. I said a long time ago that I saw possibilities in the Philippines strategy but I paired it with Mexico. A big thud! Now maybe it will be Brazil. Anyway, although there were positives and negatives in the CC, the news about the Philippines 28 should not be lightly ignored.